Connect to other sites within the UBM Medica Network
No benefit of axillary lymph node evaluation has been shown for women with DCIS, yet this lymph node analysis is still often performed in these patients. Image © Blamb / Shutterstock.com.
Too Much Imaging in Stage I and II Breast Cancer Patients
Inappropriate imaging is still performed among asymptomatic women with stage I or II breast cancer in Ontario.
ASCO Poster Sessions: Breast Cancer in Elderly Women
As physicians, we strive to do no harm, and there is a narrow therapeutic window when treating elderly patients with cancer.
Uptick in Breast-Conserving Therapy, But Disparities Still Exist
Utilization of breast-conserving therapy has increased over the years in early breast cancer but there are still barriers, including socioeconomic factors.
Breast Cancer Screening Reduces Breast Cancer Mortality
Breast cancer screening for women aged 50 to 74 does reduce breast cancer mortality.
TDM-1 Better Than Trastuzumab in HER2-, HR-Positive Breast Cancer
Neoadjuvant TDM-1 was shown to be effective in treating HER2-positive, HR-positive breast cancer compared with trastuzumab, with or without endocrine therapy.
Physical Activity Trims Breast Cancer Risk
Women who exercise may lower their risk, although those who have received hormone replacement therapy may not get the same benefit. Organized programs can help.
Neoadjuvant Pertuzumab Adds Benefit in HER2-Positive Breast Cancer
The addition of pertuzumab to trastuzumab and docetaxel offers significant improvement over other options in patients with HER2-positive breast cancer.
Palbociclib, Fulvestrant Delays HR-Positive Breast Cancer Progression
The addition of palbociclib to fulvestrant delayed disease progression in women with HR-positive, HER2-negative metastatic breast cancer.
Anastrozole Trumps Tamoxifen in DCIS
Treatment of postmenopausal DCIS patients with the aromatase inhibitor anastrozole resulted in higher breast cancer–free survival rates compared with treatment with tamoxifen.
Majority of Metaplastic Breast Cancers May Be Targetable
In this video from MBCC we discuss a poster presentation on genomic and protein alterations in 126 triple-negative metaplastic breast cancers.
Impact of ALTTO Results on Patients With HER2-Positive Breast Cancer
In this video, Dr. Sledge discusses what the negative results of the ALTTO trial mean for women with HER2-positive breast cancer.
By clicking Accept, you agree to become a member of the UBM Medica Community.